HOUSTON--(BUSINESS WIRE)--IDev Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, today announced that it has closed a $19 million Series B round of financing. Three new investors joined the financing: Rivervest Venture Partners, Bay City Capital and Heron Capital. Additionally, existing investors including PTV Sciences, members of the senior management team and advisors to the company also participated. Dennis Wahr, MD from Rivervest and Jeanne Cunicelli from Bay City Capital have been appointed to the IDev Board of Directors.
